Establishment of a method for simultaneous determination of ceftazidime，avibactam and aztreonam concentrations in human plasma
- VernacularTitle:人血浆中头孢他啶、阿维巴坦及氨曲南浓度同时测定方法的建立
- Author:
Lili WENG
1
;
Yi ZHANG
2
;
Ruixia ZHANG
2
;
Yayao LYU
2
;
Cheng ZHU
3
Author Information
1. Dept. of Pharmacy，Tianjin First Central Hospital，Tianjin 300192，China;The First Central Clinical College，Tianjin Medical University，Tianjin 300192，China
2. Dept. of Pharmacy，Tianjin First Central Hospital，Tianjin 300192，China
3. The First Central Clinical College，Tianjin Medical University，Tianjin 300192，China
- Publication Type:Journal Article
- Keywords:
ceftazidime;
avibactam;
aztreonam;
plasma concentration;
infection
- From:
China Pharmacy
2026;37(17):2292-2296
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To establish a method for simultaneous determination of ceftazidime， avibactam and aztreonam concentrations in human plasma.METHODS Stable-isotope-labeled compounds ceftazidime-D 5 ， avibactam- 13 C 5 and aztreonam- 2 H 6 were used as internal standards. Plasma samples were pretreated by protein precipitation with methanol， followed by nitrogen blowing. A ultra-performance liquid chromatography-tandem mass spectrometry （UPLC-MS/MS） technique was applied to develop a quantitative analytical method for simultaneous measurement of ceftazidime， avibactam and aztreonam in human plasma. An ACQUITY UPLC BEH C 18 column was used as the chromatographic column. Gradient elution was performed with 0.01% formic acid-acetonitrile solution as the mobile phase at a flow rate of 0.3 mL/min. The column temperature was set at 40 ℃， and the injection volume was 5 μL. An electrospray ionization source was operated in both positive and negative ion modes for multiple reaction monitoring. Method validation was carried out according to the Guidelines for Bioanalytical Method Validation contained in volume Ⅳ of the 2020 edition of Chinese Pharmacopoeia .RESULTS The linear ranges of ceftazidime， avibactam and aztreonam were 0.04-200， 0.05-50，0.01-50 μg/mL， respectively， with all correlation coefficients no less than 0.996. The relative error （RE） for accuracy was no more than 12.25% （ n ＝5）， and the RSD for precision was no more than 13.49% （ n ＝5）. The RSD of internal-standard-normalized matrix factors was less than 15.00% （ n ＝6）. The RE in stability tests was lower than 15.00% （ n ＝3）.CONCLUSIONS This study successfully established an UPLC-MS/MS method for simultaneous determination of ceftazidime， avibactam and aztreonam concentrations in human plasma. The method possesses favorable accuracy， precision and stability， and can provide methodological support for therapeutic drug monitoring and individualized medication in patients treated with these three combined drugs.
